Basal Bolus Adoption

December 11, 2019

Two Case Studies Presented at IHI National Forum Demonstrate Use of Glytec’s Technology and Services Leads to Improved Glycemic Outcomes

AdventHealth Waterman and Sentara Virginia Beach General Hospital showcased reductions in hypoglycemia and glycemic practice variation utilizing Glytec’s comprehensive systems approach to glucose management.

In partnership with clinical leaders from AdventHealth Waterman and Sentara Virginia Beach General Hospital, Glytec presented two storyboards at the IHI National Forum revealing significant quality and safety improvements for hospitalized patients receiving insulin therapy. On average, this population represents as many as one of every three patients admitted to a general ward and one of every two patients admitted to an intensive care unit. Both hospitals credit their collaboration with Glytec, including utilization of the company’s FDA-cleared decision support platform, eGlycemic Management System® (eGMS®), as well as the company’s highly-tailored quality improvement services.

November 5, 2019

Survey Reveals Better Care Needed for Hospitalized Patients with Diabetes

Results of a nationwide survey indicate most hospitals do not employ best practices in glucose control, which leads to increased safety risks, higher readmission rates and significantly greater costs.

According to a recent survey, more than 75% of U.S. hospitals employ an outdated form of insulin therapy inconsistent with recommendations by the American Diabetes Association, American Association of Clinical Endocrinologists, Society of Hospital Medicine and other authoritative sources.

November 8, 2018

Novant Health Goes Live With Glytec’s eGlycemic Management System®

The 14-hospital health system implements Glytec’s insulin therapy optimization solution and achieves rapid, broad-based adoption of basal-bolus best practice.

Novant Health has successfully partnered with Glytec to achieve best practice for insulin therapy in accordance with American Diabetes Association (ADA) and American Association of Clinical Endocrinologists (AACE) guidelines. Through a combination of Glytec’s FDA-cleared eGlycemic Management System® (eGMS®) and expert clinical change management program, Novant Health of Winston-Salem, North Carolina has now transitioned from manual, paper-based protocols for sliding-scale insulin therapy to fully integrated, computer-guided decision support for basal-bolus insulin therapy.

May 1, 2018

University of New Mexico Hospital to Bolster Patient Safety and Diabetes Care in Partnership with Glytec

New Mexico’s only academic medical center will soon implement Glytec’s evidence-based eGlycemic Management System® for best practices in insulin therapy management.

University of New Mexico Hospital, already a distinguished leader in diabetes care, is partnering with Glytec to achieve the highest levels of quality and safety for hospitalized patients who require insulin therapy. Using Glytec’s eGlycemic Management System®, the Albuquerque-based academic medical center will not only introduce greater standardization and systemization around best practices in glycemic management, but will aim to realize the very significant goal of eliminating severe hypoglycemia.

January 23, 2018

Glytec’s Software Yields Superior Patient Outcomes According to Four New Studies in Journal of Diabetes Science and Technology

Safety and efficacy of Glytec’s eGlycemic Management System® for diabetes therapy management, and its advantages over conventional methods, is further validated by four peer-reviewed studies.

Four new studies published in the January 2018 issue of Journal of Diabetes Science and Technology (JDST) demonstrate superior patient outcomes and organizational performance with Glytec’s eGlycemic Management System® (eGMS®) versus conventional, paper-based protocols. In all instances, which included both inpatient and outpatient settings, use of eGMS® for diabetes and insulin therapy management was observed to be safer and more effective than ‘usual care,’ with lower rates of hypoglycemia, faster resolution of diabetic ketoacidosis (DKA), expedited time to target glucose, and sustained reductions in A1c. Additionally, use of eGMS® led to substantive efficiency gains in provider workflows, fewer point-of-care tests, shorter lengths of stay, and full adoption of best practices, including 96% utilization of basal bolus insulin.

December 5, 2017

Chesapeake Regional Healthcare will Implement Glytec’s Software to Bolster High-Reliability Care

Glytec’s eGlycemic Management System® will ensure clinicians have ready access to evidence-based decision support for personalized insulin therapy management.

Fostering a culture of patient safety is integral to the care Chesapeake Regional Healthcare delivers, and a new partnership with Glytec will enable best practices in glycemic management across all inpatient service lines. Glytec’s eGlycemic Management System® will support the optimization of intravenous and subcutaneous insulin therapy during hospitalization, and will provide evidence-based guidance on transitions in insulin therapy from hospital to home.

September 23, 2017

Glytec Moves Beyond Clinical Results to Touting Savings

The growing importance of quality ratings will put pressure on hospitals to meet ADA standards for insulin therapy without added manpower.

This June, Glytec came to the American Diabetes Association (ADA) Scientific Sessions with a new story to tell. In years past, Glytec came to ADA armed with data showing that eGMS, a cloud-based glycemic management decision support system, offered a superior way for hospitals to manage insulin therapy for patients. Company officials brought a new focus to the 77th Scientific Sessions in San Diego, California, saying that it’s not enough to offer better time in range. Glytec wants to show how its results translate into what matters most to payers – and a hospital’s bottom line.

June 21, 2017

With Glytec, Hospital Moves to Basal-Bolus Insulin, Saves $9.7 Million

The move to quality ratings will put more pressure on hospitals to find ways to improve the standard of care while cutting costs.

A decade ago, the American Diabetes Association (ADA) called for hospitals to shift from sliding scale to subcutaneous basal-bolus insulin therapy for non-critically ill patients, but change has been slow in coming. Fear of hypoglycemia and concerns that staff would not be able to keep up with dosing demands of basal-bolus kept hospitals from upgrading to the standard of care.

June 20, 2017

Raymie McFarland Discusses Findings From Glytec’s Basal-Bolus Insulin Study

Glytec’s eGlycemic Management System (eGMS) helped the Kaweah Delta hospital shift its standard of care to basal-bolus insulin, explained Raymie McFarland, vice president of Quality Initiatives at Glytec. Basal-bolus is considered best practice and is safer for patients, but many hospitals have not adopted it due to its difficulty. Glytec hopes its eGMS can change that.

The poster that’s being presented is a case study looking at a 500-plus bed hospital in the San Joaquin Valley of California. It’s a facility named Kaweah Delta Regional Medical Center. Kaweah Delta is a very interesting case in that they did not have expertise from an endocrinology standpoint either in or outside the hospital or the health system facilities.

June 7, 2017

Case Studies Presented at Diabetes Technology Society Conference Highlight Millions in Hospital Cost Savings with Improved Glucose Control

One study presented at the International Hospital Diabetes Meeting observed first-year cost savings of nearly $7.5 million stemming from adoption of best practice for insulin therapy.

A series of studies and presentations included in the 6th International Hospital Diabetes Meeting highlighted the high cost of poor glucose management, and in particular, severe hypoglycemia (< 40 mg/dL) in the acute care setting. With thirty to forty percent of ALL hospitalized patients requiring insulin therapy, not just those with diabetes, the common problem of insulin mismanagement has significant impact on care quality, patient safety and patient experience, as well as cost and value.

May 8, 2017

Computer-Guided Insulin Titration Helps Hospitals Meet Basal Bolus Standard, Study Finds

An analysis of an electronic glucose management system developed by Glytec, which helps nurses safely manage basal bolus insulin dosing in the hospital, was presented at the recent meeting of the American Association of Clinical Endocrinologists (AACE) 26th Annual Scientific and Clinical Congress, held in Austin, Texas.

The movement toward quality ratings — and an increased emphasis on preventing readmissions — demanded solutions that help hospitals achieve the standard, which ADA clarified in January 2017 to state that basal bolus insulin was the preferred treatment for noncritically ill patients, and that, “Prolonged sole use of sliding scale insulin in the inpatient hospital setting is strongly discouraged.”

Improving Quality of Care with Electronic Glycemic Management System

At AACE 2017, Jagdeesh Ullal, MD, MS, Eastern Virginia Medical School discussed data from his team’s study that assessed the efficacy of an electronic glycemic management system (eGlycemic Management System) in controlling blood sugars in the hospital setting.

The study was conducted at Wake Forest, but the data was collected across 9 hospitals including about 1600 patients. Ullal explained that patients with diabetes come to the hospital often have high levels of blood sugar. “In our study, the patients, on average, had blood sugar levels of 200 when they came in, and over the course of their stay, their blood sugars were brought back to the normal range (140-180). We were able to achieve that with the eGlycemic Management System software that has also been proven in various other aspects of glucose management in the hospital.”

May 4, 2017

Study Shows Computer-Guided Insulin Titration Enables Basal Bolus Standard of Care

New research presented at the AACE 26th Annual Congress further validates that use of Glytec’s eGlycemic Management System® eliminates barriers to adoption of basal bolus insulin and produces superior patient outcomes.

A multi-center post-hoc analysis presented at the American Association of Clinical Endocrinologists (AACE) 26th Annual Scientific & Clinical Congress by Drs. Jagdeesh Ullal and Joseph Aloi demonstrates that Glytec’s eGlycemic Management System® (eGMS®) enables hospitals to achieve the basal bolus standard of care for subcutaneous insulin therapy with extraordinary efficiency and superior patient outcomes. The new research study, entitled ‘AUTO Study, AUtomatic Titration tO Target: Subcutaneous Basal Bolus Insulin Management Using eGMS in the Non-ICU Setting,’ observed a 19% reduction in average daily blood glucose between admission and discharge — with 0.00% severe hypoglycemia < 40 mg/dL -- while achieving the prescribed target blood glucose of 140-180 mg/dL at all mealtime and bedtime intervals.

February 7, 2017

Novant Health Partners with Glytec to Advance Leadership Position in Patient-Centered Diabetes Care

Glytec’s solution will enable the 14-hospital health system to achieve best practice, reduce variability and standardize care for patients with diabetes.

Becoming a national leader in diabetes care is a commitment Novant Health, headquartered in Winston-Salem, North Carolina, will advance through a new partnership with Glytec. The company’s patented eGlycemic Management System® (eGMS®) will be a focal point of the health system’s diabetes service line, offering clinicians a comprehensive set of tools, technologies and processes proven to achieve full adoption of basal-bolus insulin therapy, the standard of care and best practice endorsed by the American Diabetes Association (ADA) and American Association of Clinical Endocrinologists (AACE).

October 4, 2016

Study Published by Journal of Diabetes Science and Technology Demonstrates Glytec’s Superiority in Meeting ADA Guidelines

Better patient outcomes point to use of a fully automated insulin dosing decision support system as the new standard of care for basal-bolus therapy.

A study published in the Journal of Diabetes Science and Technology (JDST) provides further evidence that Glytec’s patented eGlycemic Management System® (eGMS®) is safer and more effective than traditional approaches to managing basal-bolus therapy. With some 40% of hospitalized patients receiving insulin therapy during their stay, the consequences of inadequate and imprecise dosing — including increased risk of complications and mortality, longer lengths of stay, and higher readmission rates — pose significant cost and quality improvement opportunities for hospitals.

May 13, 2014

Glytec Announces Late Breaking Abstracts Accepted for Poster Presentations at American Association of Clinical Endocrinologists 23rd Annual Scientific & Clinical Congress

Conducted by researchers from Duke University School of Nursing, Piedmont Healthcare, Jackson Madison County General Hospital, Sentara Health System and Eastern Virginia Medical School, the poster presentations will highlight research results evaluating Glytec’s eGlycemic Management System® in three leading acute care hospitals.

Glytec, LLC, a clinical information technology company dedicated to the mission of improving insulin management and glycemic control, announced today that several late breaking abstracts featuring the company’s eGlycemic Management System have been accepted for poster presentations at the American Association of Clinical Endocrinologists 23rd Annual Scientific and Clinical Congress, taking place from May 14 – May 18, 2014, in Las Vegas. The posters will be displayed from 9:30 a.m. to 1:00 p.m. on Saturday, May 17th in the General Poster Sessions in the exhibit hall. Presentations by the lead authors will occur from 9:45 a.m. to 11:00 a.m. on Saturday, May 17th.

Eastern Virginia Medical School Study Indicates Major Glycemic Improvement in Subcutaneous Basal Bolus Insulin Delivery Using eGlycemic Management System

Poster presented during AACE shows improved outcomes using Glytec’s subcutaneous insulin dosing solution versus traditional basal bolus insulin therapy.

Glytec, a clinical information technology company solely dedicated to the mission of improving insulin management and glycemic control, is pleased to share the results of a late-breaking poster that was presented at the American Association of Clinical Endocrinologists (AACE) 23rd Annual Scientific and Clinical Congress. The poster is based on results experienced by Sentara Healthcare during the first 30 days after using Glytec’s Glucommander™ SubQ to manage subcutaneous Basal Bolus Insulin (BBI) therapy. The poster was presented by Joseph Aloi, MD, clinical director of the Strelitz Diabetes Center at Eastern Virginia Medical School, during the Congress’s general poster session.